Table 3.
Prevalence and concordance between clinician-collected anorectal swabs and serology to detect type-specific HPV among men who reported receiving ≥1 dose of the HPV vaccine (n = 29).
| Type-Specific HPV | DNA Anorectal Swabs n, % |
Serology n, % |
% Agreement a | Kappa (95% CI) | ||
|---|---|---|---|---|---|---|
| 6 | 2 | 6.9% | 25 | 86.2% | 20.7% | 0.02 (−0.02 to 0.06) |
| 11 | 0 | 0.0% | 22 | 75.9% | 24.1% | - |
| 16 | 0 | 0.0% | 26 | 89.7% | 10.3% | - |
| 18 | 0 | 0.0% | 16 | 55.2% | 44.8% | - |
| 31 | 3 | 10.3% | 17 | 58.6% | 44.8% | 0.03 (−0.16 to 0.22) |
| 33 | 1 | 3.4% | 7 | 24.1% | 72.4% | −0.06 (−0.19 to 0.06) |
| 35 | - | - | 19 | 65.5% | - | - |
| 45 | 1 | 3.4% | 17 | 58.6% | 44.8% | 0.05 (−0.05 to 0.15) |
| 52 | 2 | 6.9% | 12 | 41.4% | 51.7% | −0.13 (−0.31 to 0.04) |
| 58 | 1 | 3.4% | 15 | 51.7% | 44.8% | −0.07 (−0.20 to 0.06) |
a Percent agreement: Sum of results positive for both swabs/serology and negative for both swabs/serology out of all test results in vaccinated MSM.